COMPANY PROFILE

Linnaeus Therapeutics

Explore full profile

Development stage biotech company

Haddonfield, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Linnaeus Therapeutics

Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company, was founded in 2018 by Dr. Todd Ridky, a physician-scientist at the University of Pennsylvania, and his then-graduate student, Christopher Natale, who now serves as the company's Director of Research. The company is a spinout from the University of Pennsylvania and is focused on the development and commercialization of novel small-molecule oncology therapeutics.

The company's lead candidate, LNS8801, is a small molecule that has shown promise in preclinical studies for its ability to target a protein that is believed to play a role in the development of cancer. Linnaeus is currently conducting a Phase 1 clinical trial of LNS8801 in patients with advanced cancers.

The company's business model is to develop and commercialize its own proprietary drugs. Linnaeus has raised over $1.6 million in funding from investors.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Haddonfield, United States
Employees: 5
Open positions: None listed
Dealroom signal: 57.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Feb 2026	$0	—	Advanced Research Projects Agency for Health - ARPA-H	↗
LATE VCEquity / VC	Aug 2024	$1.6M	$6.5M	Undisclosed	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Linnaeus Therapeutics website traffic

Latest recorded traffic for Linnaeus Therapeutics is 1.6K monthly website visits, down 5.9% over the last three months. Linnaeus Therapeutics's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change-5.9% 1-year team growth0%

Monthly website visitsJun 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired	40	$126M	$3B
ATAbdera TherapeuticsUses antibody engineering to design and develop new precision radiotherapeutics for cancer	South San Francisco, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
NUNuvalentTargeted small-molecule cancer therapies for kinase-driven cancers	Cambridge, United States	Acquired
ATAi TherapeuticsAI Therapeutics - Deep Learning Precision Medicine	Guilford, United States	Acquired
QUQualisuredxDeveloping molecular tests that enhance cancer care by identifying features that help oncologists to personalize treatments	Calgary, Canada	Operational
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational
MBMyricx BioNovel antibody-drug conjugate payloads for cancer treatment	London, United Kingdom	Acquired